115 related articles for article (PubMed ID: 28628631)
1. Computational explanation for bioactivation mechanism of targeted anticancer agents mediated by cytochrome P450s: A case of Erlotinib.
Ai CZ; Liu Y; Li W; Chen DM; Zhu XX; Yan YW; Chen DC; Jiang YZ
PLoS One; 2017; 12(6):e0179333. PubMed ID: 28628631
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.
Li X; Kamenecka TM; Cameron MD
Drug Metab Dispos; 2010 Jul; 38(7):1238-45. PubMed ID: 20382753
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4.
Kalgutkar AS; Henne KR; Lame ME; Vaz AD; Collin C; Soglia JR; Zhao SX; Hop CE
Chem Biol Interact; 2005 Jun; 155(1-2):10-20. PubMed ID: 15978881
[TBL] [Abstract][Full Text] [Related]
4. QM/MM modeling of benzene hydroxylation in human cytochrome P450 2C9.
Bathelt CM; Mulholland AJ; Harvey JN
J Phys Chem A; 2008 Dec; 112(50):13149-56. PubMed ID: 18754597
[TBL] [Abstract][Full Text] [Related]
5. A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome p450 enzymes.
de Visser SP; Shaik S
J Am Chem Soc; 2003 Jun; 125(24):7413-24. PubMed ID: 12797816
[TBL] [Abstract][Full Text] [Related]
6. Understanding P450-mediated Bio-transformations into Epoxide and Phenolic Metabolites.
Tomberg A; Pottel J; Liu Z; Labute P; Moitessier N
Angew Chem Int Ed Engl; 2015 Nov; 54(46):13743-7. PubMed ID: 26418278
[TBL] [Abstract][Full Text] [Related]
7. Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes.
Zhao H; Li S; Yang Z; Peng Y; Chen X; Zheng J
Drug Metab Dispos; 2018 Apr; 46(4):442-450. PubMed ID: 29352069
[TBL] [Abstract][Full Text] [Related]
8. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4.
Kalgutkar AS; Vaz AD; Lame ME; Henne KR; Soglia J; Zhao SX; Abramov YA; Lombardo F; Collin C; Hendsch ZS; Hop CE
Drug Metab Dispos; 2005 Feb; 33(2):243-53. PubMed ID: 15523046
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases.
Venkataraman H; den Braver MW; Vermeulen NP; Commandeur JN
Chem Res Toxicol; 2014 Dec; 27(12):2071-81. PubMed ID: 25372302
[TBL] [Abstract][Full Text] [Related]
10. One-electron oxidation of diclofenac by human cytochrome P450s as a potential bioactivation mechanism for formation of 2'-(glutathion-S-yl)-deschloro-diclofenac.
Boerma JS; Vermeulen NP; Commandeur JN
Chem Biol Interact; 2014 Jan; 207():32-40. PubMed ID: 24246759
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based inactivation of cytochromes by furan epoxide: unraveling the molecular mechanism.
Taxak N; Kalra S; Bharatam PV
Inorg Chem; 2013 Dec; 52(23):13496-508. PubMed ID: 24236636
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems.
Guengerich FP; Johnson WW
Biochemistry; 1997 Dec; 36(48):14741-50. PubMed ID: 9398194
[TBL] [Abstract][Full Text] [Related]
13. Herbal bioactivation, molecular targets and the toxicity relevance.
Chen XW; Serag ES; Sneed KB; Zhou SF
Chem Biol Interact; 2011 Jul; 192(3):161-76. PubMed ID: 21459083
[TBL] [Abstract][Full Text] [Related]
14. Conformational turn triggers regio-selectivity in the bioactivation of thiophene-contained compounds mediated by cytochrome P450.
Ai CZ; Liu Y; Chen DC; Saeed Y; Jiang YZ
J Biol Inorg Chem; 2019 Oct; 24(7):1023-1033. PubMed ID: 31506822
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
16. Modeling the Bioactivation and Subsequent Reactivity of Drugs.
Hughes TB; Flynn N; Dang NL; Swamidass SJ
Chem Res Toxicol; 2021 Feb; 34(2):584-600. PubMed ID: 33496184
[TBL] [Abstract][Full Text] [Related]
17. Detoxification of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by cytochrome P450 enzymes: A theoretical investigation.
Li XX; Wang Y; Zheng QC; Zhang HX
J Inorg Biochem; 2016 Jan; 154():21-8. PubMed ID: 26544505
[TBL] [Abstract][Full Text] [Related]
18. An in silico design of bioavailability for kinase inhibitors evaluating the mechanistic rationale in the CYP metabolism of erlotinib.
Chelli SM; Gupta P; Belliraj SK
J Mol Model; 2019 Feb; 25(3):65. PubMed ID: 30762124
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4.
Sun H; Yost GS
Chem Res Toxicol; 2008 Feb; 21(2):374-85. PubMed ID: 18095656
[TBL] [Abstract][Full Text] [Related]
20. Metabolic-intermediate complex formation with cytochrome P450: theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate.
Taxak N; Desai PV; Patel B; Mohutsky M; Klimkowski VJ; Gombar V; Bharatam PV
J Comput Chem; 2012 Aug; 33(21):1740-7. PubMed ID: 22610824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
